aTYR PHARMA INC
ATYR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001339970
No open-market purchases or sales by aTYR PHARMA INC insiders were filed in the last 90 days; 89 institutions reported holding it in 13F filings for Q2 2026, worth $23.2M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding aTYR PHARMA INC changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 47 | 41 | −6 |
| Shares | 20.6M | 19.6M | −927.1K (−4.5%) |
| Value | $153.5M | $105.0M | −$48.5M (−31.6%) |
New holders (6)
Institutions that held aTYR PHARMA INC at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Wolverine Trading, LLC | 22,089 | $120.0K | 0.00% |
| D. E. Shaw & Co., Inc. | 18,808 | $101.0K | 0.00% |
| ExodusPoint Capital Management, LP | 13,456 | $72.0K | 0.00% |
| Virtu Financial LLC | 13,126 | $70.0K | 0.01% |
| Citigroup Inc | 650 | $3.00K | 0.00% |
| Raleigh Capital Management Inc. | 600 | $3.00K | 0.00% |
Sold out (12)
Institutions that held aTYR PHARMA INC at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| EAM Investors, LLC | 252,280 | $1.89M |
| EAM Global Investors LLC | 152,792 | $1.14M |
| Gsa Capital Partners LLP | 58,791 | $439.0K |
| Raymond James & Associates | 24,584 | $184.0K |
| Nan Fung Group Holdings Ltd | 23,500 | $176.0K |
| Millennium Management LLC | 19,656 | $147.0K |
| Goldman Sachs Group Inc | 18,512 | $138.0K |
| Trexquant Investment LP | 18,106 | $135.0K |
| Cubist Systematic Strategies, LLC | 16,900 | $126.0K |
| Jump Financial, LLC | 16,100 | $120.0K |
| Blueshift Asset Management, LLC | 12,729 | $95.0K |
| Qube Research & Technologies Ltd | 11,665 | $87.0K |